Dental Pain (Following Third Molar Tooth Extraction) Study
The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||See Detailed Description|
- Difference between treatments over time based on pain intensity and pain relief scores.
- Difference between treatments based on changes in onset, duration of activity, overall effectiveness, and patient based assessments.
|Study Start Date:||December 2004|
|Study Completion Date:||April 2005|
|Primary Completion Date:||April 2005 (Final data collection date for primary outcome measure)|
A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg, and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction
Please refer to this study by its ClinicalTrials.gov identifier: NCT00114049
|United States, Texas|
|GSK Investigational Site|
|Austin, Texas, United States, 78703|
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|